CORMEDIX INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
CORMEDIX INC. (CRMD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $115.91 thousand for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-14.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2019-11-14
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2019-09-30 was -$92.80K.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2019-06-30 was -$17.20K.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2019-03-31 was $225.92K.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2018-03-31 was $0.00, a 100.00% decline year-over-year.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2018 was $42.40K, a 221.21% increase from fiscal 2017.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2017 was $13.20K.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2015 was $3.26M, a 412.49% increase from fiscal 2014.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2014 was $636.25K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2019-09-30 | -$92.80K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$110.01K derived: sum of 2 quarters · filed 2019-11-14 | $115.91K 10-Q · filed 2019-11-14 | |
| 2019-06-30 | -$17.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $208.72K 10-Q · filed 2019-08-14 | ||
| 2019-03-31 | $225.92K 10-Q · filed 2019-05-13 | |||
| 2018-12-31 | $42.40K 10-K · filed 2019-05-29 | |||
| 2018-03-31 | $0.00 10-Q · filed 2018-05-15 | $0.00 derived: sum of 2 quarters · filed 2018-05-15 | $0.00 derived: sum of 3 quarters · filed 2018-05-15 | $0.00 derived: sum of 4 quarters · filed 2018-08-14 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-19 | $0.00 derived: sum of 2 quarters · filed 2018-03-19 | $0.00 derived: sum of 3 quarters · filed 2018-08-14 | $13.20K 10-K · filed 2018-03-19 |
| 2017-09-30 | $0.00 10-Q · filed 2017-11-09 | $0.00 derived: sum of 2 quarters · filed 2018-08-14 | $13.20K 10-Q · filed 2018-11-14 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $13.20K 10-Q · filed 2018-08-14 | ||
| 2017-03-31 | $13.20K 10-Q · filed 2018-05-15 | |||
| 2016-09-30 | $486.55K 10-Q · filed 2017-11-09 | $1.47M 10-Q · filed 2017-11-09 | ||
| 2016-06-30 | $980.04K 10-Q · filed 2017-08-09 | |||
| 2015-12-31 | $3.26M 10-K · filed 2016-03-15 | |||
| 2014-12-31 | $636.25K 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |